Quaternary salts as hypoglycemic agents |
| OF THE INVENTION The hypoglycemic agents of the present invention are synthesized by the reaction ... |
|
Pasteurized therapeutically active protein compositions |
| What is claimed is: 1. A method of pasteurizing a composition comprising a thermally sensitive, ... |
|
Method of preparing a high-purity, virus safe, biologically active transferrin preparation |
| We claim: 1. A method of preparing a high-purity, virus-safe biologically active, transferrin ... |
|
Hydrolyzable resin composition and an antifouling coating composition containing the same |
| What is claimed is: 1. A method of preventing marine fouling which comprises applying to a surface ... |
|
Treatment for herpes virus |
| OF THE INVENTION According to the invention, I provide a composition for and method of use of such ... |
|
Microbicidal meta oxy- and thio-substituted phenylanilines |
| What is claimed is: 1. A compound of the formula I, including salts and metal complexes thereof ##ST... |
|
Substituted acyl derivatives of amino acids |
| OF THE INVENTION The invention in its broad aspects includes substituted acyl derivatives of amino ... |
|
Escherichia coliO-polysaccharide-protein conjugate vaccine |
| OF THE INVENTION The present invention relates to E. coli-protein conjugates for use in vaccines ... |
|
|
Terminal methionyl bovine growth hormone and its use
| Details |
Inventors: de Boer, Herman A.; Heynerer, Herbert L.; Seeburg, Peter H.;
Assignee: Genentech, Inc. (South San Francisco, CA)
Primary Examiner: Griffin; Ronald W.
Assistant Examiner: Moezie; F. T.
Attorney, Agent or Firm:
Novel amino terminal methionyl embodiments of bovine growth hormone are prepared in recombinant cell culture. Amino terminal methionyl derivatives of bovine growth hormone are particularly useful in enhancing milk production by dairy cattle. |
|
DETAILED DESCRIPTION According to the present invention, synthetic DNA is provided for a substantial portion of the initial coding sequence of a heterologous gene insert, and optionally, upstream therefrom through the ATG translational start codon and ribosome binding site. The critical portion of DNA is chemically synthesized, keeping in mind two factors: (1) the creation of a sequence that codes for the initial (N-terminus) amino acid sequence of a polypeptide comprising a functional protein or bioactive portion thereof and (2) the assurance that said sequence provides, on transcription, messenger RNA that has a secondary/tertiary conformational structure which is insufficient to interfere with its accessibility for efficient ribosomal translation, as herein defined. Such chemical synthesis includes standard organic synthesis using modified mononucleotides as building blocks such as according to the method of Crea et al. , Nucleic Acids Research 8, 2331 (1980) as well as the use of site directed mutagenesis of DNA fragments such as according to the method of Razin et al. , Proc. Natl. Acad Sci (USA) 75, 4268 (1978) and the use of synthetic primers on certain appropriately sequenced DNA fragments followed by specific cleavage of the desired region. The present invention is directed to a process of preparing DNA sequences comprising nucleotides arranged sequentially so as to encode the proper amino acid sequence of a given polypeptide. This method involves the obtainment of a substantial portion of the DNA coding sequence of a given polypeptide via means other than chemical synthesis, most often by reverse transcription from requisite tissue and/or culture cell messenger RNA. This fragment encodes the C-terminal portion of the polypeptide and is ligated, in accordance herewith, to a remainder of the coding sequence, obtained by chemical synthesis, optionally including properly positioned translational start and stop signals and upstream DNA through the ribosome binding site and the first nucleotide (+1) of the resultant messenger RNA
|
| Related patents |
|
|
Human immune interferon
The present invention is based upon the discovery that recombinant DNA technology can be used to successfully produce human immune interferon, preferably in direct form, ...
|
|
|
Method for production of an enzyme granulate
I claim: 1. In a process for production of an enzyme granulate which comprises granulating an enzyme composition comprising enzyme, filler, binder, and from 1.5-40% by ...
|
|
|
Process for preparing narasin
The new microorganism of this invention is a biologically pure culture derived from a soil sample collected near the Surinam River, Surinam, South America. The culture ...
|
|
|
Reversible optical waveguide vapor sensor
Accordingly, it is an object of the invention to detect small amounts of a chemical in air and in other gases. Another object is to provide a device for such purpose ...
|
|
|
Biotinidase-resistant biotinylated compound and methods of use thereof
This invention relates to biotinidase-resistant biotinylated compounds containing a chemical fragment having the structure: ##STR2## wherein R.sub.1 and R.sub.3 are ...
|
|
|
Method of recovering shiga-like toxins and vaccines comprising inactivated shiga-like toxin
This invention provides a facile, efficient and reproducible method for recovering biologically active Shiga-like toxins from a sample using an affinity ligand ...
|
|
|
Assays for shiga toxin and shiga-like toxins
OF THE INVENTION The present invention relates to a substantially pure antigenic or peptide protein related to Shiga toxin (ST) or Shiga-like toxins I or II (SLT-II, SLT...
|
|
|
Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
OF THE INVENTION Histologic examination of colonic tissue has revealed no evidence of attachment of E. coli O157:H7 to bovine colonic tissue. The rumen appears to be ...
|
|
|
Feline leukemia virus vaccines
OF THE INVENTION Any immunogenic FeLV protein may be expressed in baculovirus following the methods and techniques described here. For instance, the location and ...
|
|
|
Resolution of D,L-dehydroproline
I claim: 1. A method for the preparation of L-3,4-dehydroproline comprising in combination the steps of: A. treating N-protected D,L-3,4-dehydroproline with R(+)-alpha-...
|
|
|